The FDA just flipped the script on Moderna by advancing its mRNA-1010 biologics license application to review status, sending shares up 5.77% to $46.46 amid otherwise mixed market vibes. This latest move comes hot on the heels of a prior refusal-to-file letter that left many traders scrambling. You know how it goes—news hits, desks react, and if you blinked, you missed the surge.
U-Turn Drama: From Refusal to Review
Just last week, the FDA was stonewalling, rejecting mRNA-1010 due to its standard-dose seasonal flu vaccine comparator choice. Fast forward a few days and it’s now all systems go with a PDUFA goal date set for August 5, 2026, aimed squarely at adults aged 50 and over—including those 65+. If it gets across the finish line in time for the upcoming flu season? That's a game-changer.
On top of this rollercoaster ride, Moderna reported a fourth-quarter loss of $2.11 per share but managed to beat expectations by around 48 cents; analysts were bracing for an even worse hit of $2.59. The cherry on top? Quarterly sales came in at $678 million—way above forecasts of $626 million—which has got desks buzzing about potential revenue growth trajectories.
Market Signals: Strength or Stumble?
Diving deeper into technicals reveals some mixed signals amidst this volatility storm. The stock is perched 6.6% above its 20-day simple moving average (SMA) and an eye-popping 49.6% above its longer-term SMA—a bullish sign on paper, right? But hold up; while shares are sitting pretty near their year-long highs with a nifty increase of nearly 23%, other indicators tell a less rosy story.
The RSI sits at a neutral zone of 58.53—neither screaming 'buy' nor 'sell'. Meanwhile, MACD is below its signal line—suggesting bearish undertones lurking beneath that shiny surface.
This cocktail of neutral RSI with bearish MACD throws cold water on any outright confidence in sustained upward momentum ahead—traders should tread carefully here as they navigate these murky waters.
